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Background.Chronic cannabis use has become prevalent with decriminalization,medical prescription, and recreational legalization
in numerous US states. With this increasing incidence of chronic cannabis use a new clinical syndrome has become apparent
in emergency departments and hospitals across the country, termed Cannabinoid Hyperemesis (CH). CH has been described as
cyclical vomiting and abdominal pain in the setting of chronic cannabis use, which is often temporarily relieved by hot showers. CH
presents a diagnostic challenge to clinicians who do not have a high clinical suspicion for the syndrome and can result in high costs
and resource utilization for hospitals and patients. This study investigates the expenditures associated with delayed CH evaluation
anddelayed diagnosis.Methods.This is a retrospective observational study of 17 patients diagnosedwithCHat threemedical centers
in the United States from 2010 to 2015, consisting of two academic centers and a community hospital. Emergency department (ED)
costs were calculated and analyzed for patients eventually diagnosed with CH. Results. For the 17 patients treated, the total cost
for combined ED visits and radiologic evaluations was an average of $76,920.92 per patient. On average these patients had 17.9 ED
visits before the diagnosis of CH was made. Conclusion. CH provides a diagnostic challenge to clinicians without a high suspicion
of the syndrome andmay become increasingly prevalent with current trends toward cannabis legalization.The diagnosis of CH can
be made primarily through a thorough history and physical examination. Awareness of this syndrome can save institutions money,
prevent inappropriate utilization of healthcare resources, and save patients from unnecessary diagnostic tests.
1. Introduction
In 2004, Allen et al. recognized and introduced a new
clinical syndrome surrounding chronic cannabis use, coining
it Cannabinoid Hyperemesis (CH) [1]. CH is characterized
by cyclical vomiting and abdominal pain, both of which are
temporarily relieved by hot showers [1]. The only known
curative measure is cessation of cannabis use, while its rein-
troduction eventually leads to a recurrence of the symptoms.
Simonetto et al. further clarified the criteria for diagnosis of
CH to be (1) recurrent vomiting that is (2) preceded by long-
term cannabis use and (3) not explained by any other major
illness.
Subsequent to its description, there have been many case
reports and series confirming the existence of CH [2]. In
spite of Allen’s first presentation in 2004, a lack of clinical
recognition of this common condition persists. In fact, until
recently, this condition was referred to as “rare” in the
literature [3]. With steady advances in recreational cannabis
legalization throughout the United States, the syndrome’s
representation in the literature is increasingly prevalent, but
an objective cost analysis of delayed CH diagnosis has yet
to be described [4–6]. Legalization of cannabis in Colorado
alone has led to a twofold increase in the presentation of this
syndrome [7]. In addition, the frequent recommendation that
cannabis be used for the treatment of nausea will inevitably
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result in a further increased incidence of this syndrome.
CH has been underappreciated in ED settings, leading to
increased expenditures and unnecessary radiation exposure
when diagnosis is delayed [8].
The association of chronic cannabinoid use and cyclical
vomiting remains a paradox that has been theorized to be
due to several mechanisms, including fat-soluble prolonga-
tion of cannabinoid half-life, delayed gastric emptying, and
thermoregulatory disturbances via the limbic system [2, 9].
An intriguing and consistent component of these cases, which
is necessary for the diagnosis, is compulsive bathing and
showering in hot water, which provides transient relief of
symptoms. It has been proposed that chronic stimulation
of CB1 vascular receptors in the gut leads to their post
synaptic upregulation in the splanchnic circulation. This
increased upregulation, similar to the regulation found in gut
vascular receptors during sepsis and later stages of cirrhosis,
can lead to hyperperfusion of the viscera, which might
cause abdominal pain. It is possible that the upregulated
CB1 receptor-mediated vasodilation of the abdominal viscera
contributes to the symptoms caused by chronic cannabinoid
use. The transient relief of symptoms following prolonged
warm bathing or showering may be related to a redistribution
of blood flow from the gut to the skin. This relief of symp-
toms caused by the proposed redistribution of blood flow
from the splanchnic circulation to the cutaneous circulation
has been described as the “Cutaneous Steal Syndrome”
[9].
CH has also been described in patients after the use
of synthetic cannabis-like substances [10]. It can there-
fore be anticipated that the combination of the previously
documented increase in incidence of CH, associated with
legalization of cannabis, the recommendation of medicinal
cannabis, and the aforementioned proliferation of synthetic
cannabis products, will lead to an overall dramatic increase
in the presentation of these patients to the ED [7, 8, 10].
Radiologic costs have recently been shown to be the
greatest expense in ED visits for abdominal pain with a
low rate of true positive findings [11]. As CH patients have
multiple ED admissions and many radiologic tests prior to
diagnosis, the costs of undiagnosed CH are likely high and
even harmful to patients. Previously, there have only been
preliminary analyses of the cost of CH in ED settings [12].
In order to quantify the cost associated with delayed CH
diagnosis and work-up, we have reviewed a convenience
sample of patients presenting with a final diagnosis of CH
and calculated the cost for the ED and radiologic diagnostic
evaluation prior to the final diagnosis.
2. Methods
This was a retrospective observational study of 17 patients
diagnosed with CH at three medical centers in the United
States from 2010 to 2015, consisting of two academic centers
and a community hospital. Diagnosis of CH was made
clinically when patients met all four of the following criteria:
(1) intractable abdominal pain, nausea, and/or vomiting, (2)
relief of pain and nausea (with or without vomiting) by hot
baths or showers, (3) history of daily cannabis use, and (4)
Table 1: Costs of delayed diagnosis of CH in ED hospital visits (ED:
emergencydepartment;AAS: acute abdominal series; CT: computed
tomography; US: ultrasound).
Number of ED Admissions Per Patient 17.9
Average Total ED Charge $ 36,188.52
Average Number of X-Rays 0.9
Average Total Cost of X-Rays $756.78
Average Number of AAS 5
Average Total Cost of AAS $4,189.50
Average Number of CTs 4.9
Average Total Cost of CTs $31,092.23
Average Number of US 2.4
Average Total Cost of US $4,063.89
Average Total Cost of All Imaging $40,102.40
Average Total Cost Incurred Per Patient $76,290.92
∗X-ray is constituted by a single radiograph. An acute abdominal series
(AAS) is a radiological exam consisting of a series of radiographs that
includes an erect kidney ureter and bladder (KUB) projection, a recumbent
KUB projection, and a left lateral decubitus image of the abdomen.
absence of another obvious cause of symptoms. Charts were
then reviewed for patients who were diagnosed with CH at
one of the participating institutions from 2010 to 2015. In
order to evaluate the cost of delayed CH diagnosis, patients
with four or more admissions to the ED, who met the CH
diagnosis criteria at each of these visits, from 2010 to 2015
were enrolled in the study. Patients were cross-referenced
to ensure that they were not counted as participants at the
other study hospitals. Total ED costs were calculated based
on patient charges for the ED visits, and various radiographic
testing including X-rays, CT scans, and ultrasounds; the
median cost between the three institutions of each measured
metric was used. ED costs were defined as the costs incurred
while the patients were in the ED, and hospital costs were
excluded from the analysis.
3. Results
For the 17 patients seen, the total cost for combined ED visits
and radiologic evaluations was an average of $76,920.92 per
patient (Table 1).
On average these patients had 17.9 ED visits before the
diagnosis of CH was made, with a range from 5 to 38 visits
per person and incurred per-patient total radiologic costs
ranging from $17,133 to $210,010 (Supplemental Table 1). Until
the diagnosis of CH was made, patients were exposed to
an average of 5.94 radiographs, 4.94 CT scans, and 2.41
ultrasounds (Supplemental Table 1). In addition, among the
17 patients included, there were 58 total hospital admissions,
3 surgical interventions (an appendectomy and two cholecys-
tectomies), 8 colonoscopies, and 17 esophagoduodenoscopies
(EGDs).
4. Discussion
CH has become a much more commonly recognized disease
process as cannabis use has become much more transparent
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with the decriminalization and legalization of cannabis in
numerous US states. An increase in patients presenting with
CH, coupled with its underrecognition in the ED, is costly
and leads to wasted resources and unnecessary radiation
exposure, evidenced by the average CH evaluation cost prior
to diagnosis of $76,290.92 per patient in these three hospitals
under study.
We elected to present the radiologic data as it pertains to
CH because of its objective quantitation among institutions;
however the actual costs of misdiagnosis of CH are far
greater. As indicated by the results above, there were a
very large number of total inpatient hospitalizations, EGDs,
and colonoscopies and even three surgical interventions. It
is important to note that these hospitalizations, surgeries,
and interventions revealed no pathology other than two
patients diagnosed with unspecific gastritis. These data are
not included in the costs of delayed diagnosis of CH but
are mentioned to convey the further economic burden and
exposure of unnecessary interventions in patients eventually
diagnosed with CH.
Furthermore, radiological burden onpatients undergoing
CT scans and radiograph studies is not insignificant. Hall
et al. have showed that excess relative risk is statistically
significant at only 35mSv of radiation exposure [13]. A typical
dose from a diagnostic CT scan is 10–20 MsV, exposing our
cohort to 49.4–98.8 mSv during their evaluation. It should be
noted that individual risk has been shown to be small and
difficult to quantify and current epidemiologic studies of the
subject have yet to be published. For a population perspective,
however, it is estimated that 1.5-2.0% of all cancers in the
United States may be attributed to radiation from CT studies
[14].
Being a diagnosis based largely on history and phys-
ical examination, physicians cognizant of CH who main-
tain a high degree of suspicion for presentation in their
patient populations, can enable considerable savings and
prevent unnecessary testing. Informing ED clinicians of
CH is therefore universally beneficial, especially given
its infancy in mainstream medical literature as of 2018
[3].
Limitations of this study begin with a small sample
size as it was based on chart review from two academic
medical centers and a community hospital and was com-
prised of only 17 patients with a final diagnosis of CH.
Second, only patients with a diagnosis of CH who had
at least four visits to the ED meeting CH diagnosis cri-
teria were included in the study, which does not account
for any patients who may have received a CH diagnosis
before the fourth visit. This methodology could potentially
overestimate average cost incurred by patients before CH
diagnosis but was chosen to attempt to evaluate the cost
of delayed CH diagnosis. However, charges for laboratory
tests, medications, IVs, and inpatient costs were excluded
from the analysis which would have increased the cost
incurred per patient. Finally, the cost incurred per patient
was calculated based only on what was billed to each patient,
rather than what was paid by the patient and their insurance
company, which does not account for differences in insurance
reimbursement.
5. Conclusion
CH provides a diagnostic challenge to clinicians without a
high suspicion of the syndrome. The diagnosis of CH can
be made primarily through a thorough history and physical
examination. CH patients often havemultiple ED admissions
and many radiologic tests prior to diagnosis. The costs of
undiagnosed CH are high and even potentially harmful to
patients [15]. Awareness of this syndrome and high clinical
suspicion can save institutions money, prevent inappropriate
utilization of healthcare resources, and save patients from
unnecessary diagnostic tests.
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